The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
The Neurotoxicant, Cuprizone, as a Model to Study Demyelination and Remyelination in the Central Nervous System
Open accessAbstract
Myelin of the adult CNS is vulnerable to a variety of metabolic, toxic, and autoimmune insults. That remyelination can ensue, following demyelinating insult, has been well demonstrated. Details of the process of remyelination are, however difficult to ascertain since in most experimental models of demyelination/remyelination the severity, localization of lesion site, or time course of the pathophysiology is variable from animal to animal. In contrast, an experimental model in which massive demyelination can be reproducibly induced in large areas of mouse brain is exposure to the copper chelator, cuprizone, in the diet. We review work from several laboratories over the past 3 decades, with emphasis on our own recent studies, which suggest an overall picture of cellular events involved in demyelination/remyelination. When 8 week old C57BL/6 mice are fed 0.2% cuprizone in the diet, mature olidgodendroglia are specifically insulted (cannot fulfill the metabolic demand of support of vast amounts of myelin) and go through apoptosis.This is closely followed by recruitment of microglia and phagoctytosis of myelin. Studies of myelin gene expression, coordinated with morphological studies, indicate that even in the face of continued metabolic challenge, oligodendroglial progenitor cells proliferate and invade demyelinated areas. If the cuprizone challenge is terminated, an almost complete remyelination takes place in a matter of weeks. Communication between different cell types by soluble factors may be inferred. This material is presented in the context of a model compatible with present data—and which can be tested more rigorously with the cuprizone model. The reproducibility of the model indicates that it may allow for testing of manipulations (e.g. available knockouts or transgenics on the common genetic background, or pharmacological treatments) which may accelerate or repress the process of demyelination and or remyelination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The C57BL/6 mice showed a dramatic loss of myelin staining at this time point (Fig. 1b), which is consistent with previous reports [5].”
From Strain differences in cuprizone induced demyelination (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Upon treatment with cuprizone, mice typically exhibit profound demyelination in the corpus callosum, the cortex and the superior cerebellar peduncles [4, 5].”
From Strain differences in cuprizone induced demyelination (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most investigators use the standard C57BL/6 mouse strain in the cuprizone model to study the different molecular components involved in the complex pathogenic processes leading to corpus callosum demyelination [5].”
From Strain differences in cuprizone induced demyelination (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the corpus callosum, apoptosis of oligodendrocytes is observed, together with recruitment of microglia/macrophages, astrocytes and oligodendrocyte progenitor cells (OPCs) [5, 6].”
From Strain differences in cuprizone induced demyelination (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, the continuous exposure of C57BL/6 mice to cuprizone results in a pattern of two cycles of demyelination and remyelination, followed by chronic demyelination from which animals do not recover 36, 39.”
From SJL Mice Exposed to Cuprizone Intoxication Reveal Strain and Gender Pattern Differences in Demyelination (2009) · cites this paper as [39]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, C57BL/6 mice experience a spontaneous partial remyelination after 6 weeks and then continue to demyelinate further when exposed continuously to cuprizone 36, 39.”
From SJL Mice Exposed to Cuprizone Intoxication Reveal Strain and Gender Pattern Differences in Demyelination (2009) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, unlike microglia and astrocytes in C57BL/6 mice that respond vigorously to demyelination 2, 23, 39, these cell types in SJL mice have a guarded response at midline and in the lateral region, which correlates with subdued demyelination.”
From SJL Mice Exposed to Cuprizone Intoxication Reveal Strain and Gender Pattern Differences in Demyelination (2009) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cuprizone toxicity produces profound demyelination in the white and grey matter of the brain that mirrors sites of MS pathology [46].”
From Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination (2022) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other features common to both cuprizone-induced and type 3 MS lesions are mitochondrial stress, selective loss of myelin-associated glycoprotein (MAG), lesions with indistinct borders that are not perivascular, pronounced glial activation, and lymphocyte infiltration [43, 46, 65, 69–71].”
From Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination (2022) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The histopathological hallmark of the cuprizone model as standardized by Hiremath is oligodendrocyte death and subsequent demyelination in the corpus callosum, superior cerebellar peduncles, hippocampus [42, 46–54] and several other areas of the mouse brain (reviewed in [20]).”
From Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination (2022) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Microglial activation and axonal loss positively correlate with demyelination and the reproducible lesion localization – primarily in the corpus callosum [186], cerebellar peduncle [186], hippocampus [187], and cortex [184, 185, 188] – mirrors the topographical specificity of MS pathology, including subpial cortical demyelination seen in PMS patients.”
From Insights and challenges on animal models for progressive multiple sclerosis (2026) · cites this paper as [186]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Remyelination is very robust in the cuprizone model and starts directly after demyelination is complete, irrespective if cuprizone is further fed or not (Matsushima and Morell, 2001; Hiremath et al., 2008; Gudi et al., 2009).”
From Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned (2014) · cites this paper as Matsushima and Morell, 2001
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Depletion of microglia likewise prevented the loss of oligodendrocytes (OLs) in the CC that normally results from CUP treatment (Matsushima & Morell, 2001).”
From Activated microglia drive demyelination via CSF1R signaling (2021) · cites this paper as Matsushima & Morell, 2001
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The cuprizone model involves administration of the toxin cuprizone to induce oligodendrocyte apoptosis [4, 5].”
From Strain differences in cuprizone induced demyelination (2017) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Here, we explored the effect of antibody-mediated TREM2 activation on microglia in a well-established toxin-induced model of demyelination in the CNS resulting from exposure to the copper chelator cuprizone (CPZ) in the diet [31].”
From TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis (2020) · cites this paper as [31]
The cited source says what the claim attributes to it.
In the citing paper
“These events lead to OPC recruitment, differentiation into mature OLs, and then remyelination which is almost complete within few weeks from toxin withdrawal [31].”
From TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis (2020) · cites this paper as [31]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It may suggest that NODDI could be sensitive biomarkers to probe the different stages of white matter pathology between acute demyelination and chronic demyelination (Matsushima and Morell 2001).”
From Neurite orientation dispersion and density imaging of mouse brain microstructure (2019) · cites this paper as Matsushima and Morell 2001
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Historically these cells are not linked to demyelination following cuprizone treatment because the loss of the V(D)J recombination activation gene-1 (RAG-1), which is critical for B- and T- lymphocyte generation [269], does not alter demyelination and T-cell accumulation in the corpus callosum [46, 270].”
From Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination (2022) · cites this paper as [46]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Demyelination peaks between 4.5 and 5 weeks of cuprizone exposure in the CC and between 5 and 6 weeks in the cortex and hippocampus (Hiremath et al., 1998; Matsushima and Morell, 2001; Skripuletz et al., 2008; Gudi et al., 2009; Koutsoudaki et al., 2009).”
From Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned (2014) · cites this paper as Matsushima and Morell, 2001
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Strong astrogliosis comprising hypertrophy and hyperplasia of astrocytes occurs as a response to cuprizone treatment in different white and gray matter structures for instance the CC (Matsushima and Morell, 2001; Gudi et al., 2009), hippocampus, (Koutsoudaki et al., 2009; Norkute et al., 2009), cerebellum, cortex (Skripuletz et al., 2008), and basal ganglia (Pott et al., 2009).”
From Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned (2014) · cites this paper as Matsushima and Morell, 2001
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Astrogliosis is an additional pathological hallmark of CUP treatment (Matsushima & Morell, 2001).”
From Activated microglia drive demyelination via CSF1R signaling (2021) · cites this paper as Matsushima & Morell, 2001
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Streit, W. J., Walter, S. A., & Pennell, N. A. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00069-0 · Cited by 1,096
Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice
Hiremath, M. M., Saito, Y., Knapp, G. W., Ting, J. P.-Y., Suzuki, K., & Matsushima, G. K. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00168-4 · Cited by 412
Self-citation(1978) · PubMed · Cited by 297
Nishiyama, A., Lin, X., Giese, N. A., Heldin, C., & Stallcup, W. B. (1996) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19960201)43:3 · Cited by 244
Insulin-Like Growth Factor-1 Inhibits Mature Oligodendrocyte Apoptosis during Primary Demyelination
Mason, J. L., Ye, P., Suzuki, K., D'Ercole, A. J., & Matsushima, G. K. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-15-05703.2000 · Cited by 237
Self-citationKomoly, S., Hudson, L. D., Webster, H. D., & Bondy, C. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1894 · Cited by 223
Blakemore, W. F. (1972) · Journal of Neurocytology · doi:10.1007/bf01102943 · Cited by 217
Gene Expression in Brain during Cuprizone-Induced Demyelination and Remyelination
Morell, P., Barrett, C. V., Mason, J. L., Toews, A. D., Hostettler, J. D., Knapp, G. W., & Matsushima, G. K. (1998) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1998.0715 · Cited by 213
Self-citationDemyelination of the superior cerebellar peduncle in the mouse induced by cuprizone
Blakemore, W. F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90118-4 · Cited by 207
Blakemore, W. F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90119-6 · Cited by 177
Research works printed but not linked: 2
- Jurevics HA, 2000, Lipid metabolism during remyelination in brain, J Neurochem, 74, S32
- Ludwin SK, 1980, Chronic demyelination inhibits remyelination in the central nervous system, Lab Invest, 43, 382
Cited by
Sorted by citations
Items 501–600 of 985
Engineering biomaterial microenvironments to promote myelination in the central nervous system
Unal, D. B., Caliari, S. R., & Lampe, K. J. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.07.013 · Cited by 24
Myelination- and immune-mediated MR-based brain network correlates
Cerina, M., Muthuraman, M., Gallus, M., Koirala, N., Dik, A., Wachsmuth, L., Hundehege, P., Schiffler, P., Tenberge, J., Fleischer, V., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01827-z · Cited by 23
Plant, S. R., Wang, Y., Vasseur, S., Thrash, J. C., McMahon, E., Bergstralh, D. T., Arnett, H. A., Miller, S. D., Carson, M. J., Iovanna, J., et al. (2005) · Glia · doi:10.1002/glia.20297 · Cited by 25
An integrated approach to design novel therapeutic interventions for demyelinating disorders
Vidaurre, Ó. G., Liu, J., Haines, J. D., Sandoval, J., Nowakowski, R. S., & Casaccia, P. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.08118.x · Cited by 23
Bhattacharjee, A., Ghosh, S., Chatterji, A., & Chakraborty, K. (2020) · Metallomics · doi:10.1039/d0mt00168f · Cited by 23
TMEM106B regulates microglial proliferation and survival in response to demyelination
Zhang, T., Pang, W., Feng, T., Guo, J. D., Wu, K., Santos, M. N., Arthanarisami, A., Nana, A. L., Nguyen, Q., Kim, P. J., et al. (2023) · Science Advances · doi:10.1126/sciadv.add2676 · Cited by 23
Dynamics of reactive astrocytes fosters tissue regeneration after cuprizone‐induced demyelination
Schröder, L., Mulenge, F., Pavlou, A., Skripuletz, T., Stangel, M., Gudi, V., & Kalinke, U. (2023) · Glia · doi:10.1002/glia.24440 · Cited by 25
Mechanisms Governing Oligodendrocyte Viability in Multiple Sclerosis and Its Animal Models
Lei, Z., & Lin, W. (2024) · Cells · doi:10.3390/cells13020116 · Cited by 23
p75NTR independent oligodendrocyte death in cuprizone‐induced demyelination in C57BL/6 mice
Copray, J. C. V. M., Küst, B. M., Mantingh‐Otter, I., & Boddeke, H. W. G. M. (2005) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2005.00656.x · Cited by 23
Xu, H., & Li, X. (2011) · Schizophrenia Research and Treatment · doi:10.1155/2011/826976 · Cited by 23
Noble, M., Scott‐Hewitt, N., & Folts, C. J. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.228712 · Cited by 23
Cuprizone-induced demyelination in the mouse hippocampus is alleviated by phytoestrogen genistein
Ohgomori, T., & Jinno, S. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.11.009 · Cited by 24
Roth, L. M., Zidane, B., Festa, L. K., Putatunda, R., Romer, M. A., Monnerie, H., Jordan‐Sciutto, K. L., & Grinspan, J. B. (2020) · Glia · doi:10.1002/glia.23902 · Cited by 24
Motavaf, M., Sadeghizadeh, M., Babashah, S., Zare, L., & Javan, M. (2020) · PubMed Central · doi:10.22037/ijpr.2020.112952.14033 · Cited by 25
Narayanan, V., Cerina, M., Göbel, K., Meuth, P., Herrmann, A. M., Fernández‐Orth, J., Stangel, M., Gudi, V., Skripuletz, T., Daldrup, T., et al. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.07.010 · Cited by 23
Cognitive disturbances in the cuprizone model of multiple sclerosis
Kopanitsa, M. V., Lehtimäki, K. K., Forsman, M., Suhonen, A., Koponen, J., Piiponniemi, T. O., Kärkkäinen, A., Pavlidi, P., Shatillo, A., Sweeney, P. J., et al. (2020) · Genes Brain & Behavior · doi:10.1111/gbb.12663 · Cited by 24
Fouad, G. I. (2023) · Cardiovascular Toxicology · doi:10.1007/s12012-022-09776-0 · Cited by 22
Laquinimod prevents cuprizone-induced demyelination independent of Toll-like receptor signaling
Kramann, N., Menken, L., Hayardeny, L., Hanisch, U., & Brück, W. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000233 · Cited by 22
Petiet, A., Aigrot, M., & Stankoff, B. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00491 · Cited by 22
Pinzón, N. E., Sanz‐Morello, B., Brevé, J. J. P., Bol, J. G. J. M., Drukarch, B., Bauer, J., Baron, W., & van Dam, A. (2017) · Scientific Reports · doi:10.1038/srep40995 · Cited by 25
Protective potential of dimethyl fumarate in a mouse model of thalamocortical demyelination
Cerina, M., Narayanan, V., Delank, A., Meuth, P., Graebenitz, S., Göbel, K., Herrmann, A. M., Albrecht, S., Daldrup, T., Seidenbecher, T., et al. (2018) · Brain Structure and Function · doi:10.1007/s00429-018-1680-7 · Cited by 22
Abakumova, T. O., Kuzkina, A., Zharova, M. V., Pozdeeva, D. A., Gubskiy, I. L., Shepeleva, I. I., Antonova, O. M., Nukolova, N. V., Kekelidze, Z. I., & Chekhonin, V. P. (2015) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-015-2903-z · Cited by 23
An initial top-down proteomic analysis of the standard cuprizone mouse model of multiple sclerosis
Partridge, M. A., Gopinath, S., Myers, S. J., & Coorssen, J. R. (2015) · Journal of Chemical Biology · doi:10.1007/s12154-015-0138-0 · Cited by 22
Franco‐Pons, N., Tomàs-Roig, J., Roig, B., Auladell, C., Martorell, L., & Vilella, E. (2008) · Journal of Molecular Neuroscience · doi:10.1007/s12031-008-9151-x · Cited by 24
Thalamocortical-auditory network alterations following cuprizone‐induced demyelination
Ghaffarian, N., Mesgari, M., Cerina, M., Göbel, K., Budde, T., Speckmann, E., Meuth, S. G., & Gorji, A. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0629-0 · Cited by 24
Ozsvár, A., Szipöcs, R., Ozsvár, Z., Baka, J., Barzó, P., Tamás, G., & Molnár, G. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.01.003 · Cited by 24
Sobel, R. A., & Moore, G. W. (2008) · CRC Press eBooks · doi:10.1201/b13319-21 · Cited by 22
Mitochondrial changes in leukocytes of patients with optic neuritis.
Bosley, T. M., Constantinescu, C. S., Tench, C. R., & Abu‐Amero, K. K. (2007) · PubMed · Cited by 22
de Jong, C. G. H. M., Stancic, M., Pinxterhuis, T. H., van Horssen, J., van Dam, A., Gabius, H., & Baron, W. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly081 · Cited by 21
Transferrin Enhances Microglial Phagocytic Capacity
Carden, T. R., Correale, J. D., Pasquini, J. M., & Pérez, M. J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1519-0 · Cited by 21
Blocking the Thrombin Receptor Promotes Repair of Demyelinated Lesions in the Adult Brain
Yoon, H., Choi, C., Triplet, E. M., Langley, M. R., Kleppe, L. S., Kim, H. N., Simon, W. L., & Scarisbrick, I. A. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.2029-19.2019 · Cited by 22
Roufagalas, I., Avloniti, M., Fortosi, A., Xingi, E., Thomaidou, D., Probert, L., & Kyrargyri, V. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105449 · Cited by 23
Xing, J., Rheaume, B. A., Kim, J., Łukomska, A., Sajid, M. S., Damania, A., & Trakhtenberg, E. F. (2023) · Development · doi:10.1242/dev.201311 · Cited by 22
Remyelination in animal models of multiple sclerosis: finding the elusive grail of regeneration
Packer, D., Fresenko, E. E., & Harrington, E. P. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1207007 · Cited by 21
Remyelinating effect driven by transferrin‐loaded extracellular vesicles
Mattera, V., Occhiuzzi, F., Correale, J., & Pasquini, J. M. (2024) · Glia · doi:10.1002/glia.24478 · Cited by 21
Heterogeneity in oligodendroglia: Is it relevant to mouse models and human disease?
Ornelas, I. M., McLane, L. E., Saliu, A., Evangelou, A. V., Khandker, L., & Wood, T. L. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23900 · Cited by 22
Relationship of iron metabolism and short-term cuprizone treatment of c57bl/6 mice
Pandur, E., Pap, R., Varga, E., Jánosa, G., Komoly, S., Fórizs, J., & Sipos, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092257 · Cited by 21
Mitochondrial complex IV is lost in neurons in the cuprizone mouse model
Varhaug, K. N., Kråkenes, T., Alme, M. N., Vedeler, C. A., & Bindoff, L. A. (2019) · Mitochondrion · doi:10.1016/j.mito.2019.09.003 · Cited by 21
Radecki, D. Z., Messling, H. M., Haggerty-Skeans, J. R., Bhamidipati, S. K., Clawson, E. D., Overman, C. A., Thatcher, M. M., Salzer, J. L., & Samanta, J. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.10.003 · Cited by 21
Biase, A. D., Salvati, S., Benedetto, R. D., Attorri, L., Martinelli, A., & Malchiodi‐Albedi, F. (2013) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2013.11.004 · Cited by 21
Current and Future Applications of Transcriptomics for Discovery in CNS Disease and Injury
Munro, K. M., & Perreau, V. M. (2009) · Neurosignals · doi:10.1159/000231897 · Cited by 21
Drøjdahl, N., Fenger, C., Nielsen, H. H., Owens, T., & Finsen, B. R. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10860 · Cited by 21
Zhu, Q., Tan, Z., Zhao, S., Huang, H., Zhao, X., Hu, X., Zhang, Y., Shields, C. B., Uetani, N., & Qiu, M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.08.062 · Cited by 20
The potential of repurposing clemastine to promote remyelination
Yamazaki, R., & Ohno, N. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1582902 · Cited by 22
Czepiel, M., Leicher, L., Becker, K., Boddeke, E., & Copray, S. C. V. M. (2014) · Stem Cells Translational Medicine · doi:10.5966/sctm.2014-0041 · Cited by 20
The complexities of investigating mitochondria dynamics in multiple sclerosis and mouse models of MS
Atkinson, K. C., Osunde, M., & Tiwari-Woodruff, S. K. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1144896 · Cited by 21
Bénardais, K., Gudi, V., Gai, L., Nessler, J. N., Singh, V., Prajeeth, C. K., Skripuletz, T., & Stangel, M. (2014) · Glia · doi:10.1002/glia.22706 · Cited by 19
Gender influence on schizophrenia‐relevant abnormalities in a cuprizone demyelination model
Valeiras, B., Rosato Siri, M. V., Codagnone, M., Reinés, A., & Pasquini, J. M. (2014) · Glia · doi:10.1002/glia.22704 · Cited by 20
Sun, J., Zhou, H., Bai, F., Ren, Q., & Zhang, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.8981 · Cited by 20
Trépanier, M., Hildebrand, K. D., Nyamoya, S., Amor, S., Bazinet, R. P., & Kipp, M. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14335 · Cited by 21
Myelin and traumatic brain injury: The copper deficiency hypothesis
Klevay, L. M. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.09.011 · Cited by 20
Structural adaption of axons during de‐ and remyelination in the Cuprizone mouse model
Pfeiffer, F., Frommer‐Kaestle, G., & Fallier‐Becker, P. (2019) · Brain Pathology · doi:10.1111/bpa.12748 · Cited by 22
Hoyos, H. C., Marder, M., Ulrich, R., Gudi, V., Stangel, M., Rabinovich, G. A., Pasquini, L. A., & Pasquini, J. M. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-40764-7_15 · Cited by 21
Didonna, A., Cantó, E., Shams, H., Isobe, N., Zhao, C., Caillier, S. J., Condello, C., Yamate-Morgan, H., Tiwari-Woodruff, S. K., Mofrad, M. R. K., et al. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.04.003 · Cited by 19
Paton, K. F., Robichon, K., Templeton, N., Denny, L., Abadey, A. A., Luo, D., Prisinzano, T. E., Flamme, A. C. L., & Kivell, B. M. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.782190 · Cited by 20
Al-Otaibi, K. M., Alghamdi, B. S. A., Al-Ghamdi, M. A., Mansouri, R. A., Ashraf, G. M., & Omar, U. M. (2023) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.1068736 · Cited by 20
Zhai, D., Yan, S., Samsom, J., Wang, L., Su, P., Jiang, A., Zhang, H., Jia, Z., Wallach, I., Heifets, A., et al. (2023) · Science Advances · doi:10.1126/sciadv.adj6187 · Cited by 19
Promoting remyelination for the treatment of multiple sclerosis: opportunities and challenges
Zhang, Y., Guo, T. B., & Lu, H. (2013) · Neuroscience Bulletin · doi:10.1007/s12264-013-1317-z · Cited by 19
Li, W. S., Long, J. A., Watts, L. T., Shen, Q., Liu, Y., Zhao, J., & Duong, T. Q. (2016) · NMR in Biomedicine · doi:10.1002/nbm.3536 · Cited by 19
Xiu, Y., Cheng, G., Peng, C., Wang, Y., Li, Y., Chao, F., & Tang, Y. C. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23997 · Cited by 22
Multiple Sclerosis: Basic and Clinical
Buzzard, K. A., Chan, W. H., Kilpatrick, T. J., & Murray, S. S. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-57193-5_8 · Cited by 26
Oveland, E., Nystad, A. E., Berven, F. S., Myhr, K., Torkildsen, Ø., & Wergeland, S. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.008 · Cited by 18
Active Induction of Experimental Autoimmune Encephalomyelitis in C57BL/6 Mice
Contarini, G., Giusti, P., & Skaper, S. D. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7571-6_26 · Cited by 19
Xing, B., Brink, L. E., Maers, K., Sullivan, M. L. G., Bodnar, R. J., Stolz, D. B., & Cambi, F. (2018) · Glia · doi:10.1002/glia.23453 · Cited by 19
Hill, I., Palombo, M., Santin, M. D., Branzoli, F., Philippe, A.-C., Wassermann, D., Aigrot, M., Stankoff, B., Evercooren, A. B., Felfli, M., et al. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117425 · Cited by 26
Wang, J., Luo, Y., Tang, J., Liang, X., Huang, C., Gao, Y., Qi, Y., Yang, C., Chao, F., Zhang, Y., et al. (2020) · The Journal of Comparative Neurology · doi:10.1002/cne.24914 · Cited by 19
Zhang, N., Jin, L., Liu, C., Zhang, R., Siebert, H., Li, Y., Loers, G., Petridis, A. K., Xia, Z., Dong, H., et al. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2020.104309 · Cited by 19
Relevance of biometals during neuronal differentiation and myelination: in vitro and in vivo studies
Chin-Chan, M., Montes, S., Blanco-Álvarez, V. M., Aguirre‐Alarcón, H., Rodríguez, I. H., & Bautista, E. (2022) · BioMetals · doi:10.1007/s10534-022-00380-x · Cited by 19
Early regional cuprizone‐induced demyelination in a rat model revealed with MRI
Oakden, W., Bock, N. A., Al‐Ebraheem, A., Farquharson, M., & Stanisz, G. J. (2017) · NMR in Biomedicine · doi:10.1002/nbm.3743 · Cited by 20
Xue, Y., Zhu, X., Yan, W., Zhang, Z., Cui, E., Wu, Y., Li, C., Pan, J., Yan, Q., Chai, X., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.860280 · Cited by 19
The Role of Vitamin K in the Development of Neurodegenerative Diseases
Diachenko, A. I., Родин, И. А., Krasnova, T. N., Klychnikov, O. I., & Нефедова, Л. Н. (2024) · Biochemistry (Moscow) · doi:10.1134/s0006297924140049 · Cited by 18
ApTOLL: A new therapeutic aptamer for cytoprotection and (re)myelination after multiple sclerosis
Fernández‐Gómez, B., Marchena, M., Piñeiro, D., Gómez‐Martín, P., Sánchez-Jiménez, E., Laó, Y., Valencia, G., Nocera, S., Benítez‐Fernández, R., Castaño-León, A. M., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16399 · Cited by 19
Gresle, M. M., Butzkueven, H., Perreau, V. M., Jonas, A., Xiao, J., Thiem, S., Holmes, F. E., Doherty, W. O. S., Soo, P. Y., Binder, M. D., et al. (2015) · Glia · doi:10.1002/glia.22798 · Cited by 18
Chen, L.-P., Li, Z.-Y., Ping, M., Li, R., Liu, J., Xie, X., Song, X.-J., & Guo, L. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.06.063 · Cited by 17
Glatiramer promotes oligodendroglial cell maturation in a cuprizone-induced demyelination model
Rosato‐Siri, M. V., Badaracco, M. E., & Pasquini, J. M. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.04.008 · Cited by 17
Kondo, M., Fukudome, D., Smith, D. R., Gallagher, M., Kamiya, A., & Sawa, A. (2016) · Neuroscience Research · doi:10.1016/j.neures.2016.01.006 · Cited by 18
Zahednasab, H., Firouzi, M., Kaboudanian-Ardestani, S., Mojallal-Tabatabaei, Z., Karampour, S., & Keyvani, H. (2018) · Cytokine · doi:10.1016/j.cyto.2018.10.016 · Cited by 19
Eberle, D., Fodelianaki, G., Kurth, T., Jagielska, A., Möllmert, S., Ulbricht, E., Wagner, K., Taubenberger, A. V., Träber, N., Escolano, J.-C., et al. (2020) · Brain Multiphysics · doi:10.1016/j.brain.2020.100019 · Cited by 30
Abakumova, T. O., Kuzkina, A., Zharova, M. E., Pozdeeva, D. A., Gubskiy, I. L., Shepeleva, I. I., Antonova, O. M., Nukolova, N. V., Kekelidze, Z. I., & Chekhonin, V. P. (2015) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-015-2976-8 · Cited by 18
Briggs, D. T., Martin, C. B., Ingersoll, S. A., Barnum, S. R., & Martin, B. K. (2007) · Glia · doi:10.1002/glia.20551 · Cited by 17
Intrinsic organization of the corpus callosum
Barbaresi, P., Fabri, M., Lorenzi, T., Sagrati, A., & Morroni, M. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1393000 · Cited by 20
Direct Lineage Reprogramming in the CNS
Bajohr, J., & Faiz, M. (2019) · Advances in experimental medicine and biology · doi:10.1007/5584_2019_374 · Cited by 18
Sex Differences in the Behavioural Aspects of the Cuprizone-Induced Demyelination Model in Mice
Paton, K. F., Hong, S., Biggerstaff, A., & Kivell, B. M. (2022) · Brain Sciences · doi:10.3390/brainsci12121687 · Cited by 19
Zhao, M., Zhu, T., Xu, D., Wan, X., Liu, G., Murayama, R., Cai, Y., Yue, Y., Wang, X.-M., Yang, J., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177096 · Cited by 17
Liang, M., Chen, Y., Zhang, L., Li, L., Chen, G., & Yin, L. (2015) · Neurochemical Research · doi:10.1007/s11064-014-1490-0 · Cited by 17
Xuan, Y., Yan, G., Peng, H., Wu, R., & Xu, H. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2014.02.004 · Cited by 17
Acrolein-mediated conduction loss is partially restored by K+channel blockers
Yan, R., Page, J. C., & Shi, R. (2015) · Journal of Neurophysiology · doi:10.1152/jn.00467.2015 · Cited by 17
The Spatial and Temporal Characters of Demyelination and Remyelination in the Cuprizone Animal Model
Zhang, Y., Cai, L., Fan, K., Fan, B., Li, N., Gao, W., Yang, X., & Ma, J. (2019) · The Anatomical Record · doi:10.1002/ar.24216 · Cited by 16
Espírito‐Santo, S., Coutinho, V. G., Dezonne, R. S., Stipursky, J., dos Santos‐Rodrigues, A., Batista, C., Paes‐de‐Carvalho, R., Fuss, B., & Gomes, F. C. A. (2021) · Glia · doi:10.1002/glia.23971 · Cited by 19
Mendiola, A. S., Church, K. A., Cardona, S. M., Vanegas, D., Garcia, S. A., Macklin, W. B., Lira, S. A., Ransohoff, R. M., Kokovay, E., Lin, C. A., et al. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15616 · Cited by 15
Guía de uso adecuado de modelos animales para el desarrollo de terapias en esclerosis múltiple
Bruna, B. M., Espejo, C., Nieto, L. M., García, M. S., López, D. C., Soubriet, F. D. C., Fernández, Ó., Montalbán, X., Villoslada, P., & Rodríguez, C. G. (2012) · Revista de Neurología · doi:10.33588/rn.5402.2011424 · Cited by 17
Cuprizone-induced demyelination in Wistar rats; electrophysiological and histological assessment.
Başoğlu, H., Boylu, N. T., & Köse, H. (2013) · PubMed · Cited by 17
Humanin affects object recognition and gliosis in short-term cuprizone-treated mice
Murakami, M., Nagahama, M., Abe, Y., & Niikura, T. (2017) · Neuropeptides · doi:10.1016/j.npep.2017.10.002 · Cited by 17
Kriszta, G., Nemes, B., Sándor, Z., Ács, P., Komoly, S., Berente, Z., Bölcskei, K., & Pintér, E. (2019) · Cells · doi:10.3390/cells9010081 · Cited by 19
Hertanu, A., Soustelle, L., Buron, J., Priellec, J. L., Cayre, M., Troter, A. L., Prévost, V., Ranjeva, J., Varma, G., Alsop, D. C., et al. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.119785 · Cited by 16
Morita, S., Tatsumi, K., Makinodan, M., Okuda, H., Kishimoto, T., & Wanaka, A. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1190-1 · Cited by 16
Nomura, T., Bandô, Y., You, H., Tanaka, T., & Yoshida, S. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2400-z · Cited by 17
Tiwari, S., Lapierre, J., Ojha, C. R., Martins, K., Parira, T., Dutta, R. K., Caobi, A., Garbinski, L. D., Ceyhan, Y., Esteban-López, M., et al. (2018) · Journal of Neuroscience Research · doi:10.1002/jnr.24322 · Cited by 16
Pathological changes in mice with long term cuprizone administration
Nomura, T., Bandô, Y., Nakazawa, H., Kanemoto, S., & Yoshida, S. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.03.018 · Cited by 16
Mu, H., Gao, X., Li, S., Wei, P., Zhao, Y., Zhang, W., Wang, Y., & Gao, Y. (2019) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13155 · Cited by 16
Metadata
- Authors
- Matsushima, G. K., & Morell, P.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Matsushima, Glenn K.
- Venue
- Brain Pathology
- Publisher
- Wiley
- Published
- 2001-01
- Volume
- 11
- Issue
- 1
- Pages
- 107-116
- ISSN
- 1015-6305 (ISSN-L)
- 1750-3639
- PMC
- PMC8098267
- OpenAlex
- W2100904149
- Cited by
- 984
- References
- 45
- Citations by year
- 2026: 31 · 2025: 38 · 2024: 42 · 2023: 50 · 2022: 58 · 2021: 48 · 2020: 55 · 2019: 75 · 2018: 59 · 2017: 65 · 2016: 39 · 2015: 58 · 2014: 39 · 2013: 53 · 2012: 40
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Brain Pathology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ns011615-29, 5r01ns037815-05, 5r29ns035372-05)
- National Institute of Neurological Disorders and Stroke (NS37815, NS-11615, NS-35372)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- cuprizone, demyelination, remyelination, oligodendrocyte apoptosis, microglia, myelin phagocytosis, oligodendrocyte precursor cells, myelin gene expression, C57BL/6 mice, copper chelators
- MeSH terms
- Animals, Central Nervous System, Chelating Agents, Cuprizone, Demyelinating Diseases, Mice, Inbred C57BL, Myelin Sheath, Oligodendroglia, Microglia, Models, Animal, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
